A Multicenter, Open-label Study of QRX003 Lotion in Participants With Netherton Syndrome
Quoin Pharmaceuticals
Summary
This is a multicenter, open-label study to evaluate the safety, tolerability, and efficacy of 4% QRX003 lotion applied twice daily (BID) for 12 weeks to Netherton syndrome (NS) diseased skin in all affected areas of the body excluding the scalp (the Treatment Area), totaling approximately 50% Body Surface Area (BSA) or more.
Eligibility
- Age range
- 4+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. Participant is male or female and at least 4 years of age. 2. Participant has provided written informed consent/assent. Based on the participant's age and local regulations , a participant under legal age of consent must provide written informed assent and be accompanied by the parent or legal guardian at the time of assent/consent signing. The parent or legal guardian must provide informed consent for the participant. If a participant reaches the age at which consent is required by local regulations during the study, the participant must provide written informed consen…
Interventions
- DrugQRX003
Serine Protease Inhibitor
Locations (5)
- Center for Dermatology Clinical ResearchFremont, California
- Yale University School of MedicineNew Haven, Connecticut
- Dawes Fretzin Clinical Reseacrh GroupIndianapolis, Indiana
- Beacon Clinical ResearchQuincy, Massachusetts
- Texas Dermatology and Laser SpecialistsSan Antonio, Texas